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Normal human and other mammalian serums contain a  protein, properdin 
(1,  2), which is an important constituent of a  natural defense mechanism of 
blood. Properdin, in conjunction with complement and Mg  ++, participates in 
the destruction of certain bacteria and abnormal red cells and in the neutrali- 
zation and inactivation of certain viruses. Properdin differs from antibody in 
many respects, particularly in its apparent lack of serological specificity, its 
requirements for Mg  ++ and complement for its interactions, and in its physi- 
cal and chemical properties. 
A  method for the assay of properdin has been briefly described elsewhere 
(1). This method depends upon the requirement of properdin for the inactiva- 
tion of the third component of complement (C'3)  by zymosan (3). A unit of 
properdin is defined as the smallest amount of test sample which will reduce 
the C'3  titer of a  properdin-deficient serum  (RP)  from 120  to 0  units during 
incubation  with  zymosan under  standard  conditions.  While  there  are  theo- 
retical and practical objections to the zymosan assay of properdin, it has been 
found  to be more reproducible and  reliable than  other types of assays now 
under  investigation.  The actual  test  is  not  difficult to  perform, but  careful 
selection and standardization of reagents are necessary. 
The present paper describes detailed procedures for the zymosan assay of 
properdin and for the preparation and standardization of reagents employed 
in this test. 
General Materials and Methods 
In this and the following papers of this series, the following symbols (4, 5) 
will be employed: 
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P  Properdin  C'3  Third component of C' 
RP  Serum deficient in properdin  C'4  Fourth component of C 
Z  Zymosan  R1  Serum deficient in C'I 
PZ  Properdin-zymosan complex  R2  Serum deficient in C'2 
C'  Complement  R3  Serum deficient in C'3 
C'1  First component of C'  R4  Serum deficient in C'4 
C'2  Second component of C' 
Human Serum.--Blood  from healthy human donors was drawn during the late afternoon 
and allowed to stand at room temperature for 2 hours. The clot was then rimmed, and the 
blood stored at 2  ° overnight. The serum was separated by centrifugation at 2  ° for 30 min- 
utes at 4000 R.P.M. and recentrifuged under identical conditions to  remove residual red cells. 
The clear serum was then stored at  1  °, if used within an 8 hour period or stored at  --70  ° 
for further use. 
pII 7.4 Barbital Buffer (5).-- 
85.0  gin.  NaC1 
5.75  "  5,5-diethylbarbituric acid 
3.75  "  sodium 5,5-diethylbarbiturate 
5.0  "  ~s MgCls 
1.5  "  ~CaC12 
The ingredients were dissolved in about 1500 ml. of hot distilled water. The solution was 
cooled, and distilled water then added to a final volume of 2 liters. This concentrated buffer 
was stored at 1 °. 1 part of the buffer was added to 4  parts of distilled water before use. The di- 
luted buffer was prepared daily and discarded after a  12 hour period. 
Sensitized Sheep  Cells.--Fresh  sheep blood was collected in an equal volume of Alsever's 
solution (5) and maintained at 1  °. The blood was stored for 4 days before use and discarded 
after 10 days. Sensitized sheep cells were prepared daily, as follows: Cells were washed twice 
with 10 volumes of 0.15 M NaC1 and then once with 10 volumes of barbital buffer. A 2 per 
cent suspension of washed ceils was then made in barbital buffer. 1 mh of this suspension 
was hemolyzed by the addition of 24 ml. of distilled water. The hemoglobin concentration 
of the hemolyzed red  cells  was determined in a  Coleman universal spectrophotometer at 
550 m/z with a  violet filter using a  water blank. The red cell suspension was diluted with 
barbital buffer to contain 5 X  10 s cells/c.mm, by reference to a standard curve relating cell 
count and optical density at 550 rag. An equal volume of barbital buffer, containing 4 units 
of amboceptor, was added quickly and with rapid mixing to the standardized sheep cells. 
The sensitized cells were used only during a  12  hour period after their preparation. 
The Titration of Human Complement  (C').--1 unit of C t is the minimum amount of serum 
necessary to produce complete hemolysis of 1 ml. of sensitized sheep cells in a  final volume 
of  15  ml.  after 30  minutes at  37 °.  Normal  serums give  values  ranging  from  25  to  75 
tmits/ml, of serum, with a  median value of about 40 units/mh of serum. The latter value 
corresponds to 0.12 ml. of a  1:5 dilution of human serum. The titration of complement was 
performed as follows:- 
Varying amounts of a  1:5 dilution of human serum ranging from 0.08  to 0.3  ml. were 
added to the series of 12  X  75 mm. serological  test tubes and sufficient barbital buffer was 
added to bring the volume to 0.5 ml. Then 1 ml. of evenly suspended sensitized sheep cells 
was added to each tube. The tubes were shaken and incubated in a water bath at 37 ° for 
30  minutes. The least amount of serum showing complete hemolysis was considered to be 
1 unit of C'. 
Titration of Components of C'.--General methods for the preparations of reagents and for 
the titration of individual components of C' have been described elsewhere (4-8). In the 
present work, the sample to be titrated was diluted serially in barbital buffer. To a  series 
of 12  X  75  mm. tubes in an ice bath, 0.2  ml. of the sample dilutions, a constant amount PILLEMER,  BLUM,  LEPOW,  WURZ,  AND  TODD 
of reagent (R1, R2, R3, or R4, depending upon the component to be titrated), and 1 ml. of 
sensitized cells were added. The contents of the tubes were mixed, incubated at 37  ° for 30 
minutes, centrifuged at 2000 R.P.~.  for 5 minutes, and compared visually with a  50 per cent 
hemolytic standard. The titer was expressed as the reciprocal of the sample dilution which 
gave 50 per cent hemolysis. This value, multiplied by 5, gives the number of units of com- 
ponent  per  milliliter  of  sample.  The  end-point  was  read  to  the  nearest  half-tube;  for 
example, if a  dilution of 1:24 gave 60 per  cent  hemolysis and  1:48  gave  40  per cent  he- 
molysis, the end-point was taken at 1:36 and the titer expressed as 180 units per ml. 
The standard precautions were taken before using C ~ reagents (5, 6). The reagents em- 
ployed were not anticomplementary or significantly hemolytic at the levels used in compo- 
nent titrations. Recombination of reagents (R1 and R2, R1 and R3, R1 and R4, etc.) was 
performed to show that each reagent was hemolyticalty inactive only because of the absence 
of the component in question. In most experiments, these criteria were met by using 3 units 
of R1, 2 units of R2, 2 units of R3, and 3 units of R4 for the titration of Cq, C~2, C'3, and 
C'4 respectively. 
Double distilled water was employed throughout. All glassware was cleaned with sodium 
dichromate-sulfuric  acid  solution  and  washed  in  distilled  water.  International  PR-I  or 
PR-II  refrigerated  centrifuges were  used  for centrifugation.  Constant temperature  baths, 
accurate to  4-0.5 °  ,  were employed for incubation. Hydrogen ion concentration was deter- 
mined with the Cambridge research model pH meter. Serum and serum reagents were stored 
at  -70 ° in a  Hudson Bay mechanical freezer. 
EXPEl~  rMENTAL 
This paper  is presented in four sections. These deal with the preparation 
and standardization of (I)  zymosan; (II)  of purified properdin;  (III)  of RP 
and R3; and (IV) with the details of the zymosan assay of properdin. Appro- 
priate methods and materials are presented in each section. 
I.  ZYMOSAN 
Zymosan (3)  is a  fine, light-gray powder insoluble in water but which dis- 
perses readily to give a homogeneous suspension. It is derived from the yeast 
cell wall.  It is composed mainly of carbohydrate as a  glucose polymer but 
contains small amounts of nitrogen, phosphorus, and magnesium. It is possible 
to remove most of the nitrogen and magnesium-phosphorus complex without 
destroying the immunological properties of zymosan (3). 
In this paper and those that follow, the term zymosan is used to designate 
the above described substances (a) that selectively inactivate C~3 when added 
to human serum and incubated at 37 °,  (b)  that will complex with properdin 
at 17 ° in the presence of C ~ and Mg  ~-, and (c)  that will form from suitable 
serums satisfactory R3 and RP which can be used as reagents for the assay 
of properdin.  Not  all yeast cell  wall preparations fulfill these requirements. 
This is shown in Table  I.  It will be  seen  that zymosan A  inactivates Ct3, 
combines with properdin, and makes suitable RP. Zymosan B does not make 
a  suitable  R3,  but  combines with properdin  and  makes a  satisfactory  RP. 
Zymosan C  inactivates C~3, combines with properdin,  but will not make a PROPERDL~ SYSTEM AND IMMUNITY 
satisfactory PP.  Zymosan D  will not  inactivate  C'3  or make a  suitable RP 
but combines with properdin. Zymosan E  is entirely inactive. It is of interest 
that  yeast glucan  (9)  combines with properdin but  does not  inactivate C'3. 
Thus,  glucan resembles zymosan B.  It has also been shown  (10)  that certain 
dextrans and levans, mucins,  endotoxins, and bacterial cell wails behave like 
zymosan A, while others show  all of the variations exhibited by types B,  C, 
D, and E. 
TABLE I 
The Effect o/Various Zymosans on the Yroperdin System in Human Serum 
Zymosan 
A 
B 
C 
D 
E 
Makes satisfactory R3 
Yes 
No 
Yes 
No 
~t 
Makes mfisfaetoryRP 
Yes 
No 
c~ 
~c 
Properdin recovered 
from PZ complex 
Yes 
ct 
ct 
No 
It is desirable to have a  zymosan preparation that can be employed for all 
the purposes described above. Such zymosan can generally be prepared by the 
modified procedure given below:- 
Preparation o/Zymosan 
1. Suspend  evenly 1 kg. of yeast in 4 liters of 0.5 ~  Na2HPO4 and boil for 3 hours. 
2.  Cool to 37 ° and add 0.5 gm. of trypsin (Wilson 1:250)  on the 1st, 3rd, 6th, and 10th 
day of incubation at 37 °. Add 5 ml. of toluene on the 1st day, and 2.5 ml. of toluene o n the 
3rd, 7th,  11th,  and 15th  day of incubation. Incubate for 16 days at 37 °, with occasional 
stirring, and adjust pH daily to 7.8-8.0  by the careful addition of NaOH. 
3.  CoUect precipitate by centrifugation.  Discard supernatant. 
4.  Suspend precipitate evenly in 4 liters of tap H20 at room temperature. Stir thoroughly 
for 1 hour, centrifuge  as in step 3 and discard supernatant. 
5.  Suspend  precipitate evenly with vigorous stirring in 4 liters of boiling tap H~O. Stir 
at 95 to 100  ° for 1 hour. Centrifuge while hot as in step 3. Repeat this step once more. 
6.  Suspend  precipitate evenly in 4 liters of boiling distilled  H20 with vigorous stirring. 
Treat and centrifuge  as in step 5.  Repeat this step one time. The  supernatant should  be 
free of soluble carbohydrate. If not, repeat washing. 
7.  The precipitate from step 6 is added rapidly with vigorous stirring:-- 
(a) to 8 liters of absohtte ethyl alcohol; stir for 1 hour; centrifuge. 
(b) The precipitate is added to 4 liters of absolute ethyl alcohol and treated as in (step a). 
(¢) The residue is dried in vacuo. 
(d) The dried powder is refluxed for 3 hours with 500 ml. of absolute ethyl alcohol. 
(e) Centrifuge  and dry immediately in vacuo and store in vacuo. 
Yield: 1 to 2 per cent. 
Care must be taken to avoid bacterial contamination during processing, to 
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drates  by  washing.  Most  of  the  difficulties in  the  preparation  of  zymosan 
occur during the treatment with ethyl alcohol. It is imperative that absolute 
ethyl alcohol be employed throughout. The use of methanol or of 95 per cent 
ethyl alcohol may yield zymosans of any of the altered types  shown above. 
Improper dehydration also  gives brownish products that are difficult to sus- 
pend in water and resemble resins in their appearance. 
Before use, zymosan is suspended as evenly as possible in  100 volumes of 
0.15 ~  NaCI. The suspension is placed in a  boiling water bath for 1 hour. It 
is then centrifuged for 30 minutes at 4000 R.P.~.,  the supernatant discarded 
and the residue suspended evenly in the diluent of choice to the desired con- 
centration. Such suspensions  can be maintained  at  1  ° for at  least  a  month, 
care being taken to avoid contamination. 
The Standardization of Zymosan.-- 
1. Each lot of zymosan is tested for the minimal amount required for the 
specific inactivation of C'3. From 0.5 to 2.0 mg. of most zymosan preparations 
are required to inactivate the C'3 in  1 ml. of human serum. In practice 0.5, 
1, 2, and 4 rag. of zymosan are each incubated with 1 ml. of serum for 1 hour 
at 37 ° with occasional mixing. The residue is removed by centrifugation and 
the supernatants  tested for C'3  activity. If complete inactivation of C'3  oc- 
curs, the sample prepared with the minimal amount of zymosan is then tested 
for C' and other C' component activities. At least 75 per cent of the original 
C'I, CP2, and C'4 should be present for a suitable reagent (R3). 
2.  While  there are marked qualitative and quantitative  differences in  the 
ability of zymosans to inactivate C'3, the amounts of most zymosans required 
for the removal of properdin from serum and for the preparation of suitable 
RP are remarkably constant. The addition of 2 to 3 rag. of zymosan to each 
ml. of serum at 17  ° for 1 hour usually removes over 90 per cent of properdin 
from human serum, yielding suitable RP and also PZ from which properdin 
may be eluted. 
3.  The optimal amount of zymosan required in  the assay of properdin is 
determined as follows: Mixtures of 0.25 ml. of RP and 0.5 ml. of buffer with 
and without 1 unit of added properdin are incubated at 37 ° for 1 hour with 
varying amounts of zymosan. The amount of zymosan employed in the assay 
of properdin is the maximal amount which will not reduce the C'3 titer of RP 
more than 25 per cent, but will completely inactivate all the C'3 in the pres- 
ence of RP  and  1 unit of added properdin. Usually,  this represents about 4 
times the amount of zymosan necessary to inactivate C'3 in untreated serum. 
II. PROPERDIN 
A general method for the isolation of properdin from human serum has been 
presented previously (1). A detailed procedure is presented here for the prepa- 100 ml. fresh human serum 
Equilibrate at 17 ±  1  °. 
Add 4 ml. zymosan suspension (50-75 mg./ml.) (A) previ- 
ously equilibrated at 17 -4- 1% 
Stir 60 rain. at 17 4- 1  °. Adjust pH and maintain at 6.9 ± 
0.2 with N HC1. 
Centrifuge immediately at 4000 R.P.~.,  1  °, 30 min. 
II 
Predpitate  =  PZ complex 
Suspend evenly in 50 ml. pH 6.0 phosphate-saline buffer (B) 
at 1  °. 
Centrifuge immediately at 40~}0 R.P.M., 1  °, 30 rain. 
Repeat above washing step two additional times. 
Supernatant  =  RP 
f 
Precipitate  =  washed PZ complex  Supernatant  =  washings 
Suspend in 36 ml. pH 7.4 Michaelis buffer (C) and 14 ml. 2 
NaC1 at 37 ±  1  °. 
Stir 60 minutes at 37 ±  1  °. 
Centrifuge immediately at 4000 R.P.M., 1  °, 60 rain. 
Precipitate  =  eluted PZ complex  Supernatant  =  properdin eluate 
Dialyze  against  three 
changes of 2  liters of dis- 
tilled water for 3  days at 
1  °  . Resistance after dialy- 
sis  should  be  <  4000 
ohms. 
Adjust pH  after  dialysis to 
5.8 ±  0.1. 
Allow to stand at least 1 hr. 
at 1  ° after adjustment 
Centrifuge at 4000 mP.M., 1  °, 
30 rain. 
Precipitate =  crude properdin 
I  Extract with 17 ml. pH 7.4 barbital buffer at 1  °. 
Centrifuge at 4000 R.P.M., 1  °, 30 min. 
Supernatant discarded 
f 
Precipitate 
i  Reextract with 8 ml. pH 7.4 barbital buffer 
at 1  °. 
Centrifuge at 4000 ~.P.~.,  1°~ 30 min. 
f-V- 
Precipitate discarded 
Supernatant A  =  properdin extract 
upernatant  B __ properdin ex_~tract 
FiG. 1.  Flow diagram for the isolation of properdin from human serum. 
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ration  of human  properdin  suitable  for  the  standardization  of  the  zymosan 
assay. This material is free of C' components, but contains traces of plasmino- 
gem The results of further purification studies and the physicochemical char- 
acterization of properdin will be described in a  subsequent publication. 
The purification procedure shown in Fig.  1 has been found to be relatively 
simple and reproducible. The average yield has been 2 to 4 units of properdin 
per ml. serum. The purification factor has been in the range of 2000-fold. The 
titration  of purified properdin is given in a  later section. 
Reagents for the Preparation of Properdin 
A.  200 to 300 rag. of zymosan is suspended evenly in 20 ml. of 0.15 M NaCI, placed in 
a  boiling water bath for I  hour, and then centrifuged at 4000 R.P.~.  for 30 minutes. 
The residue is suspended as uniformly as possible in pH 7.4 barbital buffer to a  final 
volume of 4  ml.  (50 to  75 mg./ml.). 
B. ptt 6.0 pkosphate-saline buyer 
1768.4 ml. ~a/10 Na HzPO4 
231.6 ml. ~/10 Na2HPO4 
Add 1 part of buffer to 19 parts of 0.15 ~¢ NaC1 
C. pH 7.4 Mixhadis buffer 
9.714 gin. sodium acetate (3Ho.O) 
14.714 gin. sodium 5,5-diethylbarbiturate 
17.00  gin.  NaC1 
Dissolve in 1960 ml. of H~O. Adjust pH to 7.4 4- 0.1 with about 43 ml. of ~ HC1 
m. RP n~O R3 
RP: 
The measurement of properdin activity requires an RP that is deficient  only 
in properdin.  RP must supply C~3 and an excess of all the cofactors necessary 
not only for the formation of an active PZ and for the inactivation of C'3 by 
PZ, but also adequate amounts of Cq,  C~2, and CP4 for the hemolysis of sen- 
sitized sheep cells in the final assay of properdin.  While the factors concerned 
with the properdin  system resemble  C ~ components  in  many  respects,  the 
possibility  exists (11,  12)  that  they  differ  from  C ~ components.  They  may 
reside in distinct chemical structures  or the components of C ~ may have dual 
functions. 
There are considerable variations among individual  serums in their ability 
to make suitable RP. While the reasons for these differences are obscure, it is 
obvious that  a  serum will  produce  an unsatisfactory RP  if it is deficient in 
any cofactor, either initially or as a  result of treatment with zymosan. 
It would,  perhaps,  be possible to prepare a  suitable  RP from many more 
serums by proper choice of conditions for the removal of properdin from each 
serum. However, this would be a  laborious procedure and impractical. There- 
fore,  on the  basis of present knowledge,  a  standard  procedure has been fol- 
lowed which allows the preparation of RP from about 20 per cent of the hu- PROPERDIN  SYSTEM AND  YMM'UMTY 
man serums so far tested. The age, sex, race, blood groups, etc., of the donor 
bear  no  relationship  to  the  utility  of his  serum for the  preparation  of RP. 
However, serums extremely high in properdin  (greater than 8  units/ml.)  are 
usually unsatisfactory, because they are difficult to free of properdin.  Gener- 
ally, serums low in porperdin but high in C' make satisfactory RP. It is hoped 
that work now in progress will not only clarify the nature and the stability of 
the factors required in KP, but will lead to procedures that will allow most or 
all serums to be utilized for the preparation of RP. 
Meanwhile,  sufficient  serum  for  the  preparation  of  RP  and  R3  may  be 
obtained by a  preliminary screening  of serums from several donors.  Serums 
obtained  from  the  same  donor  at  different  times  are  remarkably constant. 
TABLE  II 
Variations  in the A ctivity of RP Prepared from Different Serums 
Untreated  Zymosan added  Zymosan and properdin  added  Sample 
C'3  C'3  C'3 
RPI 
RPII 
RPIII 
RPIV 
RPV 
unlts/ml. 
120 
3O 
120 
120 
0 
unlts/ml. 
90-120 
3O 
3O 
120 
0 
umts/ml. 
o 
o 
o 
6o 
o 
All samples are incubated at 37 ° for 1 hour, The zymosan is removed by  centrifugation 
and the supernatants tested for C'3 activity. 
Thus,  the  same donor,  over a  period  of  years,  will  supply serum  that  will 
produce suitable RP or R3. 
The Preparation  of RP.--Serum is brought to and maintained at  17 °  in a 
constant  temperature  bath.  The  control  of temperature  is important.  Tem- 
peratures below 15  ° result in an incomplete removal of properdin from serum, 
while temperatures above 18  °  result in increased loss of C'3 activity.  2  to 3 
mg. of zymosan in 0.08 ml. of barbital buffer are added to each ml. of serum. 
The mixture is stirred continuously; with small volumes, it is mixed manually 
every 10 minutes. Mter 1 hour, the mixture is transferred to chilled centrifuge 
tubes and centrifuged at 4000  R.r.M.  for 30 minutes  at  1  °.  The clear super- 
natant is brought to  17 ° and 2  to 3  rag.  of zymosan in 0.08  ml.  of barbital 
buffer are again added with stirring to each ml. of treated serum. The mixture 
is incubated at 17  ° for 1 hour and centrifuged as above. The clear supernatant 
(RP) is dispensed into ignition tubes for storage at --70  ° or maintained at 1  ° 
for testing within a  12 hour period. 
The  Standardization  of RP.--A  suitable  RP  should  have  a  C'  titer  of at PILLEMER, ]]LUM~ LEPOW~ WU'RZ, AND  TODD 
least 75  per cent of the original serum.  It should  not be anticomplementary 
against fresh serum, or any of the serum reagents employed in studies on the 
properdin system. The addition  of zymosan at 37 ° for 1 hour should not de- 
press the C~3 titer to less than 75 per cent of the untreated RP. The addition 
of 1 unit of human, cow, or hog purified properdin to the RP under the above 
conditions should inactivate C~3 completely. RP should measure the properdin 
in  the serums of all species. However, there  are occasional variations in  the 
ability of an RP to measure properdin in the serums of different species. This 
resembles and  may be related  to  the  species  incompatibilities  observed  be- 
tween C' and specific antibody. 
Table  II shows  the  results  obtained  with  a  suitable  RP  and  with  those 
which  are  unsatisfactory.  RPI  is  an  ideal  reagent.  RPII lacks  sufficient  C t 
and  C'3 activities. RPIII still contains more than 0.2  unit of properdin.  Ct3 
in RPIV is not inactivated by properdin, indicating the removal or inactiva- 
tion  of one or more of the accessory factors during  its preparation.  RPV  is 
anticomplementary or lacks C'3. 
R3: 
It has  been  shown  previously that  there  is  considerable  variation  among 
serums  in  their  C~3  and  other  C t  component  activities  following  (11,  12) 
zymosan treatment  at 37 °.  A  satisfactory R3  must lack  C'3  but  contain  an 
excess of Cq, C'2, and C'4. The criteria for a suitable R3 are as rigid as those 
for RP because the assay of properdin is, indeed,  based on the specific inacti- 
vation of C~3 by PZ. Therefore, the reagent employed to measure the presence 
or absence of CP3 must be deficient only in C~3 but contain an excess of other 
C t  components. Only about  15  per cent of human serums make R3  suitable 
for use in  the  assay of properdin.  As in  the  case of the  preparation  of RP, 
work is in progress to improve present procedures and to develop other meth- 
ods for preparing R3. 
Preparation  of R3.--1  to 2 mg. of zymosan in 0.05 ml. of barbital buffer is 
added  to each ml.  of serum at 37 ° and  suspended  evenly in  the serum.  The 
mixture  is  incubated  at  37 °  for  60  minutes,  with  periodic  manual  mixing. 
After this time, it is centrifuged at 4000 g.r.~, for 30 minutes at 1  °. The clear 
supernatant is transferred to ignition tubes for storage at  -70 ° or held at 1  ° 
for use within a period of 12 hours. 
The Standardization  of R3.--R3  is  tested:  (a)  for  lysis  against  sensitized 
sheep  cells;  (b)  for  anticomplementary properties  against  small  amounts  of 
fresh serum; and  (c)  for its ability to measure Ct3  in a  standard  RP  in the 
presence and absence of zymosan and in  the presence and absence of proper- 
din. 0.1  ml. of R3 should be non-lyric for 1 ml. of sensitized sheep cells. 0.05 
ml.  of R3  should,  when added  to 0.10 ml. of a  1:15  dilution  of fresh serum, 
increase the C ~ titer of the serum at least 200 per cent. 0.05 ml. of R3 should 10  PROPERDIN  SYSTE~ AND  IM3/UNITY 
measure at least: (a)  120 units of C'3 per ml.  of RP, (b) not less than 90 units 
per  ml.  of RP  previously treated  with  zymosan  at  37 °,  and  (c)  no  C'3  in 
RP  previously treated with zymosan in the presence of 1 unit  of properdin 
per ml. of RP. 
IV, Z~OSAN  ASSAY OF PROPEP.DIN 
Principle of Assay: 
The  determination  of  the  minimum  volume of test  sample  which,  when 
incubated  1 hour at 37 °  with constant  amounts of RP  and zymosan,  com- 
pletely inactivates the C'3 in the mixture. 
Definition  of Units: 
Properdin.--I unit of properdin is that quantity which, in the presence of an 
optimal amount of zymosan, completely inactivates 120 ±  30 units of C'3 in 
1 ml. of RP during 1 hour at 37 °. For example, if 0.1 ml. of sample is the min- 
imum amount which completely inactivates 120 units of C'3 in 1 ml. of RP in 
the presence of zymosan, the sample contains 1/0.1  =  10 units of properdin 
per ml. 
C'3.--1  unit of C'3 is that quantity which, in the presence of 2 units (usu- 
ally 0.05 ml.) of R3 and 1 ml. of sensitized sheep cells in a final volume of 1.5 
ml., hemolyzes 50 per cent of the cells in 30 minutes at 37  °. For example, if 
0.2 ml. of a  1:24 dilution of sample gives 50 per cent hemolysis under these 
conditions, the concentration of C'3 is 24/0.2  =  120 units per ml. 
R3.--1 unit of R3 is equal to the smallest volume of the original serum from 
which the R3  was prepared which, when added to 1 ml. of sensitized sheep 
cells in a final volume of 1.5 ml., hemolyzes 100 per cent of the cells in 30 min- 
utes at 37  °.  For example, if 0.12 ml. of a  1:5  dilution of the original serum 
before conversion into R3  gave  100  per cent hemolysis, then 2 units  of the 
R3 prepared from it is contained in 2 X  0.12/5  =  0.05 ml. 
Procedure: 
I.  Add 0.1 ml. of a standardized suspension of zymosan to each of a  series of 13  X  100 
ram. tubes in an ice bath. 
2.  Add 0.25 ml. of RP to each tube. 
3.  To successive tubes, add decreasing amounts of the test sample; for instance, 0.25  ml. 
to the first tube, 0.12 ml. to the second, etc. 
4.  Add barbital buffer to bring the volume in each tube to a  total of 0.75  ml. 
5.  Stopper each tube, shake, and incubate for 1 hour at 37 ° with periodic shaking every 
10 minutes. 
6.  Centrifuge for 10  minutes at 2000 R.P.M. and pour the supernatants into a  series of 
empty tubes. 
The next step determines the concentration of C'3 in these supernatants. 
7.  With each supernatant from step 6, make a series of 2-fold dilutions from 1:1 to 1 : 16 PILLEMER, BL~,  LEPOW, WIFRZ, AND TODD  11 
in barbital buffer, using 0.2 ml. volumes, in 12  X  75 ram. tubes. Add 2 units (0.05 ml.) of 
R3 to each tube and make the volume to 0.3 ml. with buffer. Add 1 ml. of sensitized sheep 
cells, incubate 30 minutes at 37*, and then centrifuge $ minutes at 1500 R.v.u. 
Determine which dilution gives $0 per cent hemolysis by comparing each tube with a 
50 per cent hemolysis standard prepared by adding a trace of saponin to a mixture of 0.5 
ml. of sensitized sheep  cells and 1 ml. barbital buffer. If the 50 per cent hemolysis end-point 
is intermediate between  2 dilutions, e.g., between  1:8 and  1:16, the end-point dilution is 
taken midway at 1:12. If 1:12 is the end-point in the  C'3 titration, then the concentration 
of C'3 in the supernataut from step 6 is 12 X  1/0.2  =  60 units per ml. However,  C'3 con- 
centrations are expressed in terms of undiluted RP and, since the RP is diluted threefold in 
the supernatants at step 6, a  1:12 end-point in  the C'3 titration is read as 60  X  3  =  180 
units of C'3 per ml. of undiluted RP. If  the end-point in the C'3 titration is given by the 
undiluted supernatant from step 6, the C'3 titer is 15 units per ml. of undiluted RP.  If there 
is no trace of hemolysis, the C'3 titer is taken as 0, and it is assumed  that all the C'3 in the 
RP has been inactivated. The end-point in the properdin titration is  read as the minimal 
volume of sample in step 3 which shows complete inactivation of C'3 in step 7.  The number 
of units of properdin in the test sample is determined by dividing this volume into 0.25. 
Controls: 
At step 3,  four  control tubes are set  up  in parallel with  the  test  samples 
and  carried through  the remainder of the procedure. 
Tube A  contains 0.25  ml. RP  -4-  0.5  ml. buffer.  This is used  to determine 
the concentration of C'3 in the RP after incubation, centrifuging, etc., but in 
the absence of properdin or zymosan. 
Tube B  contains 0.25 ml. RP +  0.4 ml. buffer +  0.1  ml. of zymosan.  This 
is used  to  determine  the  loss of  C'3  in  the  presence  of zymosan but  in  the 
absence of properdin. 
Tube C  contains 0.25 ml. RP -F 0.05 ml. (0.25 unit) of purified properdin -4- 
0.35 ml. of buffer A- 0.1  ml. zymosan. This sample checks that the addition of 
1 unit of properdin (per ml. of RP) results in the complete inactivation of C'3 
in the presence of zymosan. The contents in Tube D  are identical to those in 
tube C, except that 0.125  unit  of properdin is employed instead of 0.25.  This 
measures the effect of 1/2 unit of P  (per ml. of RP). 
Typical results with the control tubes at the end of step 7  are:-- 
Tube A  120 units C'3/ml. 
Tube B  90 units C'3/ml. 
Tube C  0 units C'3/ml. 
Tube D  Trace to 15 units C~3/ml. 
For  properdin  fitrafions  on  human  or  other  serums,  additional  controls 
consisting of a  standard normal serum of the species under test are set up  at 
step 3. These standard normal serums are made up of large numbers of  indi- 
vidual normal serums of each animal species and have been carefully titrated 
against several RP and R3.  They are stored in small aliquots at --70  °. Stand- 12  PROPER.DIN SYSTEM AND IMMUNITY 
ard  normal  serums  in  this  laboratory contain  the  following concentration  of 
properdin:-- 
Human  6- 8 units/ml. 
Mouse  12-15  "  " 
Rat  25-30  "  " 
Dog  12-15  "  " 
Rabbit  8-12  "  " 
If on any particular  occasion the  titers  are  significantly higher  than  these 
values,  it  is possible:  (a)  that  the  sheep  cells  are  resistant  to  hemolysis,  (b) 
that the R3  lacks Cq,  CJ2,  or C~4, (c)  that the RP is extremely sensitive  to 
properdin,  or (d)  that R3, RP, or the test serum are anticomplementary. 
TABLE III 
Sample 
lml. RP+  1 unitP 
1  "  "  +2  "  " 
1  "  "  +4  "  " 
1  "  "  +8  "  " 
0.25 ml. of serum* +  0.75 ml. of RP$ 
0.50  "  "  "  +0.50  "  "  " 
0.75  "  "  "  +0.25  "  "  " 
Calculated 
units/ml. 
1 
2 
4 
8 
Properdin 
Found 
**nlts/rd. 
1 
2 
4 
8 
* Serum contained 8 units of properdin per ml. 
RP contained less than 0.1 unit of properdin per ml. 
Titers lower than  the expected values are usually due  to: (a)  fragile sheep 
cells,  (b)  a  lyric or non-specific R3,  (c)  an RP lacking the various factors re- 
quired  for the  combination of properdin with  zymosan, or (d)  incompatibili- 
ties between  the reagents and  test sample. 
Useful  Simplification  of the  Test: 
Since  the  end-point  in  the  properdin  titration  is  that  volume  of  sample 
which inactivates all the C~3 in the mixture,  it is not necessary to titrate  Ct3, 
but merely to determine whether it is present or absent. Thus, at step 7, it is 
sufficient merely to test the undiluted  supernatants  for CJ3. However, a  com- 
plete  C'3 titration  is  always done on the  control samples  A  and  B  to check 
that the RP has a  satisfactory C'3 titer,  both in the presence and absence of 
zymosan. 
Table  III summarizes  experiments  carried  out  to determine  the  reliability 
of  the  zymosan assay  of properdin.  Varying  amounts  of purified  properdin PILLEMER, BLUM, LEPOW, WIYRZ~ AND TODD  13 
were added  to  constant amounts of RP.  At  the same  time,  normal human 
serum was diluted with varying amounts of RP. Properdin titers were deter- 
mined on the mixtures. It will be noted that the actual properdin titers of the 
samples are  identical with the calculated titers.  It is important to  conduct 
such experiments periodically in order to verify the reliability and reproduci- 
bility of the zymosan assay. 
SUMMA.R¥ 
A detailed method for the zymosan assay of properdin is described, together 
with procedures for the preparation and standardization of reagents employed 
in the test. 
The reliability and reproducibility of the assay, as  well as its limitations, 
are discussed. 
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